http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004536825-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2002-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2004536825-A |
| titleOfInvention | Methods and substances for treating immune disorders |
| abstract | The immune response of an organism is controlled by administering to the organism a therapeutically effective amount of a compound that binds galectin. In a specific case, the compound is selected to bind to galectin-1 or galectin-3. Some therapeutic substances include natural or synthetic polymers having side groups terminated by galactose or arabinose. One group of suitable therapeutic compounds includes modified pectins or other substances having a substantially demethoxylated rhamnogalacturon backbone with rhamnose residues in the middle of the backbone. Certain therapeutics include a first functional moiety that binds to the carbohydrate binding moiety of galectin and a second functional moiety that can modify the galectin protein. |
| priorityDate | 2001-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.